CDKN3 and prostate carcinoma: Association of LGALS3 (lectin, galactoside-binding soluble 3) is reported with endometrial, breast and colorectal cancer [40-42], and CDKN3 (cyclin-dependent kinase inhibitor 3) is known to be involved in hepatocarcinogenesis and breast and prostate cancer development [43,44].